Previous Article | Next Article 
J Virol, August 1998, p. 6832-6837, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Localization of Varicella-Zoster Virus Gene 21 Protein in Virus-Infected Cells in Culture
Ravi
Mahalingam,1,*
Robert
Lasher,2
Mary
Wellish,1
Randall J.
Cohrs,1 and
Donald H.
Gilden1,3
Departments of
Neurology,1
Cellular and Structural
Biology,2 and
Microbiology,3 University of
Colorado Health Sciences Center, Denver, Colorado 80262
Received 16 October 1997/Accepted 4 May 1998
 |
ABSTRACT |
Although four varicella-zoster virus (VZV) genes have been shown to
be transcribed in latently infected human ganglia, their role in the
development and maintenance of latency is unknown. To study these VZV
transcripts, we decided first to localize their expression products in
productively infected cells. We began with VZV gene 21, whose open
reading frame (ORF) is 3,113 bp. We cloned the 5' and 3' ends and the
predicted antigenic segments of the ORF as 1292-, 1280-, and 880-bp DNA
fragments, respectively, into the prokaryotic expression vector
pGEX-2T. The three VZV 21 ORFs were expressed as approximately 75-, 73-, and 59-kDa glutathione S-transferase fusion proteins
in Escherichia coli. To prepare polyclonal antibodies that
would recognize all potential epitopes on the VZV gene 21 protein,
rabbits were inoculated with a mixture of the three fusion proteins,
and antisera were obtained and affinity purified. Immunohistochemical
and immunoelectron microscopic analyses using these antibodies revealed
VZV ORF 21 protein in both the nucleus and cytoplasm of VZV-infected
cells. When these antibodies were applied to purified VZV
nucleocapsids, intense staining was seen in their central cores.
 |
INTRODUCTION |
Varicella-zoster virus (VZV) causes
varicella (chickenpox), becomes latent in ganglia, and reactivates to
produce zoster (shingles). A knowledge of the physical state and
expression of VZV genes during latency is central to predictions
regarding the prevention of reactivation. The 124-kbp double-stranded
VZV DNA contains 71 open reading frames (ORFs) that encode 68 proteins.
Analysis of a cDNA library prepared from RNA extracted from latently
infected human ganglia revealed the transcription of VZV genes 21, 29, 62, and 63 (2, 3). VZV gene 29 encodes a major DNA-binding protein (11), and genes 62 and 63 encode immediate-early
genes (5, 7). Although the function of VZV gene 21 is
unknown, its herpes simplex virus (HSV) homolog (the UL37 protein)
exists in the nucleus and cytoplasm of infected cells (14,
17). HSV UL37 complexes with the DNA-binding protein HSV ICP8
(18). To study VZV ORF 21 further, we produced fusion
proteins and monospecific polyclonal antibodies against VZV ORF 21 and
used them to localize VZV gene 21 protein in VZV-infected cells.
 |
MATERIALS AND METHODS |
Cells and viruses.
We propagated VZV in BSC-1 cells by
cocultivating semiconfluent cultures with trypsinized infected cells as
described previously (10).
Vectors, enzymes, and chemicals.
We obtained the glutathione
S-transferase fusion vector (pGEX-2T), the GST gene fusion
system, and thrombin protease from Pharmacia Biotech, Inc. (Piscataway,
N.J.), restriction enzymes and DNA-modifying enzymes from Bethesda
Research Laboratories (Gaithersburg, Md.), calf alkaline phosphatase
and protease inhibitor cocktail (complete) from Boehringer Mannheim
Biochemicals (Indianapolis, Ind.), iodoacetamide, phenylmethylsulfonyl
fluoride, and DNase I from Sigma Chemical Co. (St. Louis, Mo.),
radiochemicals from ICN Pharmaceuticals (Costa Mesa, Calif.), and the
Vectastain Elite kit from Vector Laboratories (Burlingame, Calif.).
Primers.
We chose VZV-specific oligonucleotide primers from
published sequences (4). VZV ORF 21 is located between
nucleotides 30759 and 33872 on the virus genome. In primer P1
(5'-CTCAGCGTAGAATATACCATGGAA-3'), located between
nucleotides 30741 and 30764 on the VZV genome, the first nucleotide (at
position 30741 on the VZV genome) was changed from G to C. Primer P2
(5'-ACCCACTAAAGCGAGACATCC-3') is located between nucleotides
32013 and 32033, and primer P3 (5'-ATACAAACGAAACGCCCAGTCAATA-3') is located between nucleotides 33920 and 33945 on the VZV genome.
Construction of recombinant plasmids.
Plasmid pGEX-2T was
digested with SmaI and dephosphorylated with calf intestinal
alkaline phosphatase. We used primers P1 and P2 to amplify a 1,292-bp
segment of VZV DNA (Fig. 1, segment A) by
PCR; the fragment was then blunt ended and ligated to
SmaI-treated, dephosphorylated pGEX-2T. We used the ligation
mixture to transform Escherichia coli BL21 and selected
ampicillin-resistant colonies for propagation. We used primers P1 and
P3 to amplify a 3,203-bp DNA fragment containing the complete VZV gene
21 ORF by PCR; the fragment was then blunt ended and ligated to
SmaI-digested, dephosphorylated pGEX-2T. The ligation
mixture was used to transform E. coli BL21, and
ampicillin-resistant colonies were selected for propagation. The
recombinant clone was digested with BamHI, and the large
6,228-bp fragment (containing fragment B) was purified from a 1%
agarose gel by using Geneclean kit (Bio 101, Vista, Calif.). We
religated the 6,228-bp BamHI fragment and used it to
transform E. coli BL21; ampicillin-resistant colonies were
selected for propagation.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Cloning of fragments containing VZV ORF 21 into the
pGEX-2T expression vector. We cloned three different portions of VZV
ORF 21 DNA into pGEX-2T as follows. For clone A, a 1,292-bp fragment
containing the 5' end of VZV ORF 21 was PCR amplified, blunt ended, and
cloned at the unique SmaI site of pGEX-2T, and a 3,203-bp
DNA fragment containing the complete VZV gene 21 ORF was PCR amplified,
blunt ended, and cloned at the SmaI site of pGEX-2T. For
clone B, we digested the recombinant clone containing the 3,203-bp
insert with BamHI, and the large fragment containing the
4,948-bp vector and 1,280-bp portion of the insert containing the 3'
end of VZV ORF 21 was religated. For clone C, we cut the recombinant
clone containing the complete 3,203-bp VZV ORF 21 insert with
BamHI and BglII and religated the large fragment
containing the 4,948-bp vector and 880-bp portion of the insert
containing a predicted antigenic site (hatched rectangle). The
locations of the ampicillin resistance gene (ampr),
lacIq gene (lacIq), tac
promoter (tac), gst promoter (gst), thrombin cleavage site
(Thr), and the multiple restriction sites are indicated.
|
|
Using the PC/GENE program (Intelligenetics Inc., Mountain View,
Calif.), we identified the region between nucleotides 33087
and 33107 on the VZV genome (
4) as encoding one of the most
hydrophilic regions within VZV ORF 21. Regions with high hydrophilicity
are likely to be highly antigenic. Therefore, in addition to the
5' and
3' ends of VZV ORF 21, we cloned a segment containing the
region of
high hydrophilicity as a separate GST fusion protein.
The recombinant
clone containing the complete 3,203-bp VZV 21
ORF insert described
above was cut with
BamHI and
BglII, and the
large
(5,828-bp) fragment (containing fragment C) was purified
from a 1%
agarose gel. The 5,828-bp
BglII-
BamHI fragment
was religated
and used to transform
E. coli BL21, and
ampicillin-resistant colonies
were selected for propagation.
Expression and purification of GST fusion proteins.
We
prepared fusion proteins from E. coli BL21 containing the
recombinant clones (Fig. 1, segments A, B, and C) as described previously (8), with minor modifications. Briefly, we
induced expression with 100 mM
isopropyl-
-D-thiogalactopyranoside (IPTG) in 100-ml
cultures containing ampicillin (100 µg/ml). The bacterial cell pellet
was resuspended in phosphate-buffered saline (PBS) in the presence of
protease inhibitors (1 mM iodoacetamide, 1 mM phenylmethylsulfonyl
fluoride, and one tablet of protease inhibitor cocktail from Boehringer
Mannheim Biochemicals), treated with 10 µg of DNase I per ml in 1 mM
MnCl2-10 mM MgCl2 on ice for 1 h, and
solubilized with 1.5% Sarkosyl-2% Triton X-100. We mixed a small
portion (20 µl) of each lysate with an equal volume of 2× sample
buffer (125 mM Tris-HCl [pH 6.8], 6% sodium dodecyl sulfate [SDS],
0.2% glycerol, 10% 2-mercaptoethanol, 0.03% bromophenol blue) and
analyzed it by polyacrylamide gel electrophoresis (PAGE) on an
SDS-10% polyacrylamide gel.
We processed the GST fusion proteins in the lysates by using a Bulk GST
purification module (Pharmacia Biotech). Proteins
were bound to
glutathione-Sepharose 4B beads and washed extensively
as instructed by
the manufacturer. Because the fusion proteins
were highly insoluble
under these conditions and could not be
eluted from beads with buffers
recommended by the manufacturer,
we analyzed a small portion (20 µl)
of the washed beads on an
SDS-10% polyacrylamide gel as described
above.
Preparation of rabbit antiserum against the VZV ORF 21 fusion
proteins.
The glutathione-Sepharose 4B beads carrying the fusion
proteins were loaded on preparative SDS-10% polyacrylamide gels, and the protein bands were visualized by staining with 4 M sodium acetate.
Gel slices containing the fusion proteins were dialyzed extensively in
water, lyophilized for 16 h, powdered, resuspended in PBS, and
mixed with Freund's complete adjuvant for subcutaneous inoculation
into rabbits as described previously (11). Rabbits were
boosted once a month for 5 months with a mixture of the gel containing
the fusion proteins and Freund's incomplete adjuvant. A 1:10 dilution
of the rabbit antiserum was adsorbed with uninfected BSC-1 cells at
37°C for 1 h and at 4°C for 16 h. The adsorbed antiserum
was immunoprecipitated with 35S-labeled extracts of
uninfected and VZV-infected BSC-1 cells as described previously
(24). We exposed the fluorograph to Amersham Hyperfilm-MP
for 16 h at room temperature.
Western blot analysis of GST fusion proteins with rabbit
antiserum.
Glutathione-Sepharose 4B beads (15 µl) containing 1 to 2 µg of each of the three fusion proteins were digested with 0.3 U of thrombin and loaded onto an SDS-10% polyacrylamide gel. A Western blot was prepared as described previously (23) and incubated with VZV ORF 21 antiserum (ANTI-21) followed by alkaline
phosphatase-conjugated goat anti-rabbit immunoglobulin G (IgG),
nitroblue tetrazolium, and 5-bromo-4-chloro-3-indolylphosphate for
detection as described previously (16).
Affinity purification of ANTI-21.
Two hundred microliters of
glutathione-Sepharose 4B beads containing the fusion proteins was
incubated with 10 U of thrombin protease at room temperature for
16 h, loaded onto an SDS-8% polyacrylamide gel, and
electrophoretically transferred onto nitrocellulose as described
previously (11). The antisera were affinity purified by
using the VZV ORF 21 portion of the thrombin-cleaved fusion proteins on
the nitrocellulose membranes as described previously (15),
with minor modifications. Briefly, the proteins on the nitrocellulose
membranes were visualized with Ponceau S stain (Sigma) dialyzed in
water to remove the stain, and air dried. We pooled the membrane strips
containing the free VZV ORF 21 proteins and placed them in 4% bovine
serum albumin (BSA) in PBS for 30 min, followed by ANTI-21 diluted
1:100 in 4% BSA for 1 h at room temperature. The strips were
washed three times with PBS and soaked briefly in 0.01 M sodium
phosphate (pH 6.8). We eluted the VZV-specific antibodies by soaking
the strips at room temperature twice for 4 min each time in 500 µl of
100 mM glycine-150 mM NaCl (pH 7.5). The eluate was immediately
neutralized with 0.1 volume of 1 M sodium phosphate (pH 8.6) and used
for histochemical analysis.
Immunohistochemistry.
We applied affinity-purified ANTI-21
to acetone-fixed uninfected and VZV-infected BSC-1 cells as described
previously (13).
Immunoelectron microscopic analysis of VZV-infected BSC-1
cells.
Cells grown in 35-mm-diameter Permanox dishes were rinsed
with 0.08 M sucrose in PBS (SS buffer) and fixed in a mixture of 4%
paraformaldehyde, 15% saturated picric acid, and 0.05% glutaraldehyde in 0.1 M sodium phosphate buffer (21) on ice for 1 h,
rinsed with SS buffer, incubated in 1% sodium borohydride for 30 min at room temperature, and rinsed again in SS buffer. The cells were then
incubated for 1 h at room temperature with affinity-purified rabbit ANTI-21, rinsed with SS buffer, incubated with a 1:300 dilution
of biotinylated goat anti-rabbit IgG for 1 h at room temperature,
rinsed with SS buffer, incubated with avidin-biotin-horseradish peroxidase complex (ABC reagent; Vectastain Elite kit) for 1 h at
room temperature, and rinsed with SS buffer. We obtained the reaction
product by incubating the cells with a buffer containing diaminobenzidine, hydrogen peroxide, and nickel (Vector kit) for 2 min.
After being rinsed again with SS buffer, the cells were postfixed with
1% OsO4-0.08 M sucrose in 0.1 M sodium phosphate buffer
for 30 min, rinsed with SS buffer, and dehydrated in 50, 70, 95, and
100% ethanol followed by propylene oxide. We embedded the cells with
Spurr's resin and, after polymerization, cut thin sections with a
Reichert Ultracut E microtome. We analyzed and photographed the cells
with a Philips CM 10 electron microscope at 80 kV without additional
counterstaining. The negatives were scanned with a UMAX UC840 at 1,200 dots/in. or digitized in Kodak Photo CD pro format. Digitized images
were processed with Adobe Photoshop on a Power Macintosh 7100.
Preparation of VZV nucleocapsids.
We prepared VZV
nucleocapsids as described previously (22) and fixed the
pellets of nucleocapsids on ice with 4% paraformaldehyde-15% saturated picric acid-0.05% glutaraldehyde in 0.1 M Sorenson's phosphate buffer (pH 7.4) containing 0.08 M sucrose for 3.5 h. We
then washed the pellets and stored them in PBS containing 0.05% NaN3 at 4°C.
Immunoelectron microscopic analysis of VZV nucleocapsids.
The pellets containing fixed nucleocapsids were resuspended,
transferred to an Eppendorf tube, and centrifuged (12,000 × g) for 5 min. All but approximately 200 µl of supernatant
was aspirated mixed rapidly with 200 µl of 2% SeaKem agarose (FMC,
Rockland, Maine) at 60°C, and dispersed between two prewarmed glass
slides separated by no. 2 glass coverslips. We placed the glass slides at 4°C to gel the agarose. We then cut the agarose gel pieces into 1- to 2-mm squares and placed them into the wells of a 24-well plastic
dish containing PBS (6). The agarose pieces were then treated with 1% sodium borohydride in PBS for 30 min at room
temperature, rinsed three times with PBS, blocked with 4% BSA in PBS
containing 0.05% NaN3 and 1.5% normal goat serum
(blocking solution) for 1 h at room temperature, and then
incubated with a 1:10 dilution of either rabbit ANTI-21 or 1:10 normal
rabbit serum (NRS), both of which had been affinity purified and
adsorbed against both uninfected BSC-1 cells and a 10% homogenate of
human liver at room temperature for 15.5 h. We rinsed the agarose
pieces four times with PBS and once with the blocking solution. After 5 min, we added a 1:200 dilution of biotinylated goat anti-rabbit IgG (Vectastain Elite kit) and incubated the mixture for 2.25 h at room temperature. The pieces were then rinsed three times with PBS,
incubated with 2% BSA in PBS containing ABC reagent (Vectastain Elite
kit) for 2 h at room temperature, rinsed four times with PBS,
incubated for 2 min in
diamino-benzidine-H2O2-nickel solution (Vector
kit) at room temperature, and rinsed again four times with PBS. Samples
were then processed and examined as described for the cultured cells.
 |
RESULTS |
Expression of portions of VZV ORF 21 in E. coli and
preparation of rabbit antiserum.
We cloned three portions (the 5'
end, the 3' end, and the predicted antigenic segment) of the ORF into a
GST fusion vector (pGEX-2T) as described in Fig. 1. We used the three
recombinant clones A, B, and C (Fig. 1) to express the respective
portions of the VZV ORF 21 as GST fusion proteins in E. coli. PAGE analysis of the lysates from E. coli
containing the recombinant clones A, B, and C displayed prominent bands
at ~75, ~73, and ~59 kDa (Fig. 2,
lanes 1, 2, and 3, respectively); Fig. 2, lanes 4 to 6, also shows
purified forms of the fusion proteins bound to the Sepharose beads.
Rabbit polyclonal antisera were raised against a mixture of all three
of the 75-, 73-, and 59-kDa fusion protein bands excised from an
SDS-polyacrylamide gel. The antiserum was then affinity purified as
described in Materials and Methods.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 2.
Expression in E. coli of portions of VZV ORF
21 as GST fusion proteins. We used the recombinant clones (Fig. 1, A,
B, and C) containing portions of VZV ORF 21 to transform E. coli BL21. We induced expression of fusion proteins in 100-ml
cultures with 100 mM IPTG. The fusion proteins were prepared in the
presence of protease inhibitors and solubilized with 1.5%
Sarkosyl-2% Triton X-100. The GST fusion proteins in the lysates were
bound to GST-agarose beads and washed as described in Materials and
Methods. Twenty microliters of the lysate prepared from recombinant
clones A, B, and C (lanes 1, 2, and 3, respectively) and 20 µl of the
washed beads (lanes 4 to 6) were loaded onto an SDS-10%
polyacrylamide gel.
|
|
Western blot analysis of GST fusion proteins with ANTI-21.
The
glutathione-Sepharose 4B beads carrying the fusion proteins were
digested with thrombin and analyzed by Western blotting using the
rabbit antiserum raised against the fusion proteins. Our results showed
that the rabbit antiserum reacted with the three VZV ORF 21 polypeptides (47, 44, and 30 kDa) and the 29-kDa GST protein,
indicating that the rabbit antiserum contained antibodies specific for
the VZV ORF 21 polypeptides (Fig. 3).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of GST fusion proteins of VZV gene
21 peptides, using rabbit antiserum raised against VZV gene 21 peptides. Glutathione-Sepharose 4B beads containing 1 to 2 µg of each
of the three fusion proteins were digested with thrombin and loaded
onto an SDS-10% polyacrylamide gel, transferred to a nitrocellulose
membrane, reacted with either NRS (lane 1) or ANTI-21 (lane 2), and
visualized as described in Materials and Methods. The locations and the
sizes of the three VZV ORF 21 polypeptides (A, B, and C) and GST are
shown.
|
|
Identification of VZV gene 21 protein in virus-infected cells.
Immunoprecipitation of 35S-labeled uninfected and
VZV-infected BSC-1 cell lysates with NRS and rabbit ANTI-21 showed
detection of the 115-kDa VZV gene 21 protein with ANTI-21 but not with
NRS (Fig. 4).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoprecipitation of VZV gene 21 protein with ANTI-21.
Uninfected (U) and VZV-infected (I) BSC-1 cells were labeled with 50 µCi of [35S]methionine per ml, immunoprecipitated with
NRS or ANTI-21, and analyzed (50,000 to 100,000 cpm) by SDS-PAGE (8%
gel). The location of the ~115-kDa VZV gene 21 protein detected with
ANTI-21 and the locations of molecular weight standards (Bethesda
Research Laboratories) are indicated.
|
|
Immunohistochemical analysis of entire coverslips containing
>10
6 acetone-fixed uninfected and VZV-infected BSC-1 cells
with ANTI-21
showed VZV gene 21 protein in both the nucleus and
cytoplasm of
virus-infected cells. Positive dark red staining,
indicating the
presence of VZV gene 21 protein, was associated with the
characteristic
focal cytopathic effect produced by VZV (Fig.
5B). We did not
see staining in
uninfected cells (Fig.
5A).

View larger version (117K):
[in this window]
[in a new window]
|
FIG. 5.
Immunohistochemical staining patterns of uninfected (A)
and VZV-infected (B) BSC-1 cells after incubation with rabbit ANTI-21.
Cells on coverslips were infected with VZV. Two days later, we fixed
the cells in acetone and detected VZV gene 21 protein with rabbit
ANTI-21 followed by biotinylated goat anti-rabbit IgG and streptavidin
conjugated to alkaline phosphatase, as described in Materials and
Methods. We used new fuchsin substrate as a chromogen for detection.
Positive staining is seen in both the nucleus (arrow) and the cytoplasm
(arrowheads) of VZV-infected cells. Magnification, ×216.
|
|
We further localized the positive staining in VZV-infected cells by
immunoelectron microscopy (Fig.
6). We
examined approximately
a dozen cells. An intense VZV gene 21 signal was
associated with
developing virus particles both in the cytoplasm and in
the nucleus.
We did not quantitate virus particles. Positive staining
of purified
virus nucleocapsids with the same antibody confirmed its
specificity.
Controls using specific antibody with uninfected cells or
NRS
either with uninfected or VZV-infected cells or nucleocapsids
showed no reaction product over the virus particles or nucleocapsids.
The size of the icosahedral virus nucleocapsid was approximately
80 to
100 nm (Fig.
6h). The intact VZV particle has been shown
to be 180 to
200 nm in size (
8). Therefore, absence of positive
staining
in the 100-nm area immediately adjacent to the nucleocapsid
suggests
that VZV ORF 21 is not associated with the tegument.
The positive stain
on a few virus particles was fainter (Fig.
6b) but still darker than
the stain on particles reacted with
NRS (Fig.
6c). One possible reason
for the reduced intensity is
the tangential nature of the section of
the particles in Fig.
6b.

View larger version (154K):
[in this window]
[in a new window]
|
FIG. 6.
Immunoelectron microscopic localization of VZV gene 21 protein in VZV-infected BSC-1 cells and in purified nucleocapsids. We
incubated the fixed VZV-infected BSC-1 cells (a to c) or purified VZV
nucleocapsids (d to i) with rabbit ANTI-21 followed by biotinylated
goat anti-rabbit IgG, ABC reagent, and chromogen and prepared them for
electron microscopy as described in Materials and Methods.
Immunoreactive virus particles are seen both in the cytoplasm (arrows
in panels a and b) and in the nucleus (asterisk in panel a). The
location of the nuclear membrane is indicated by arrowheads in panels a
to c. NRS did not react with the virus particles (arrow and asterisk in
panel c). Immunoreactive cores of nucleocapsids (d and e) and
aggregates of nucleocapsids (f and g) are shown. A higher magnification
of an immunoreactive nucleocapsid core reveals their characteristic
hexagonal shape (h). NRS did not show positive staining with the
purified nucleocapsids (i). Bars = 200 nm (a to g and i) and 50 nm
(h).
|
|
 |
DISCUSSION |
We expressed three different portions of VZV ORF 21 (the 5' end,
the 3' end, and the predicted antigenic segment) as GST fusion proteins. The observed sizes of the three fusion proteins (~75, ~73, and ~59 kDa) agreed with their predicted sizes based on VZV sequence data (4) and the known size of the native GST
protein (20). Antibodies were raised in rabbits and then
affinity purified. The antiserum directed against the three fusion
proteins detected a faint band of approximately 115 kDa in
virus-infected cell lysates (Fig. 4), corresponding to the value
predicted from the amino acid sequence (4). The low
intensity of the VZV ORF 21 band seen by immunoprecipitation suggests
that the virus-encoded protein is labile or is expressed at a low level
or arises from low affinity of the antisera. The weak gene 21 signal is
not likely to be due to a low-level production of VZV proteins since
routine immunoprecipitations in our laboratory using antibodies against
other structural proteins have always yielded brighter bands
(24). Furthermore, Western blot analysis of VZV-infected
BSC-1-cell lysates also showed a weak band at 115 kDa (data not shown).
Since immunohistochemical analysis of virus-infected cells with our
affinity-purified antiserum produced a dark purple signal, it is
unlikely that this antiserum is low affinity.
Like its HSV UL37 homolog (47% similarity at the amino acid level), we
saw VZV gene 21 protein in both the nucleus and cytoplasm of
virus-infected cells (14, 17, 19). HSV UL37 has been shown
by detergent solubilization and protease treatment to be associated
with the tegument of the HSV virion (17). However, our
results indicate that VZV ORF 21 protein is not associated with the
tegument (Fig. 5h). HSV UL37 has also been shown to be a phosphoprotein
that forms a complex with the DNA-bound HSV ICP8 (1, 18).
Further analysis of VZV gene 21 protein is needed to determine its
kinetic class, whether it is phosphorylated, and if it is associated
with VZV ORF 29, a major DNA-binding protein homologous to HSV ICP8.
 |
ACKNOWLEDGMENTS |
We thank Mark Burgoon for useful suggestions, Lisa Schneck and
Mary Devlin for editorial review, and Cathy Allen for preparing the
manuscript.
This work was supported in part by Public Health Service grants AG
06127 and NS32623 from the National Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Neurology, Box B-182, University of Colorado Health Sciences Center, 4200 East 9th Ave., Denver, CO 80262. Phone: (303) 315-8100. Fax: (303)
315-8720. E-mail: ravi.mahalingam{at}uchsc.edu.
 |
REFERENCES |
| 1.
|
Albright, A. G., and F. J. Jenkins.
1993.
The herpes simplex virus UL37 protein is phosphorylated in infected cells.
J. Virol.
67:4842-4847[Abstract/Free Full Text].
|
| 2.
|
Cohrs, R.,
M. Barbour, and D. H. Gilden.
1996.
Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA.
J. Virol.
70:2789-2796[Abstract].
|
| 3.
|
Cohrs, R.,
K. Schrock,
M. Barbour,
G. Owens,
R. Mahalingam,
M. E. Devlin,
M. Wellish, and D. H. Gilden.
1994.
Varicella-zoster virus (VZV) transcription during latency in human ganglia: construction of a cDNA library from latently infected human trigeminal ganglia and detection of a VZV transcript.
J. Virol.
68:7900-7908[Abstract/Free Full Text].
|
| 4.
|
Davison, A. J., and J. E. Scott.
1986.
The complete DNA sequence of varicella-zoster virus.
J. Gen. Virol.
67:1759-1816[Abstract/Free Full Text].
|
| 5.
|
Debrus, S.,
C. Sadzot-Delvaux,
A. F. Nikkels,
J. Piette, and B. Rentier.
1995.
Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency.
J. Virol.
69:3240-3245[Abstract].
|
| 6.
|
De Camilli, P.,
S. M. Harris,
W. B. Huttner, and P. Greengard.
1983.
Synapsin I (protein I), a nerve terminal-specific phosphoprotein. II. Its specific association with synaptic vesicles demonstrated by immunocytochemistry and in agarose-embedded synaptosomes.
J. Cell Biol.
96:1355-1373[Abstract/Free Full Text].
|
| 7.
|
Forghani, B.,
R. Mahalingam,
A. Vafai,
J. W. Hurst, and K. W. Dupuis.
1990.
Monoclonal antibody to immediate early protein encoded by varicella-zoster virus gene 62.
Virus Res.
16:195-210[Medline].
|
| 8.
|
Frangioni, J. V., and B. G. Neel.
1993.
Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins.
Anal. Biochem.
210:179-187[Medline].
|
| 9.
|
Gelb, L. D.
1990.
Varicella-zoster virus, p. 2011-2054.
In
B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Virology, vol. 2. Raven Press, Inc., New York, N.Y.
|
| 10.
|
Gilden, D. H.,
Y. Shtram,
A. Friedmann,
M. Wellish,
M. Devlin,
A. Cohen,
N. Fraser, and Y. Becker.
1982.
Extraction of cell-associated varicella-zoster virus DNA with triton X-100-NaCl.
J. Virol. Methods
4:263-275[Medline].
|
| 11.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual, p. 67-69.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 12.
|
Kinchington, P. R.,
G. Inchauspe,
J. H. Subak-Sharpe,
F. Robey,
J. Hay, and W. T. Ruyechan.
1988.
Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide.
J. Virol.
62:802-809[Abstract/Free Full Text].
|
| 13.
|
Mahalingam, R.,
M. Wellish,
R. Cohrs,
S. Debrus,
J. Piette,
B. Rentier, and D. H. Gilden.
1996.
Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons.
Proc. Natl. Acad. Sci. USA
93:2122-2124[Abstract/Free Full Text].
|
| 14.
|
McLauchlan, J.,
K. Liefkens, and N. D. Stow.
1994.
The herpes simplex virus type 1 UL37 gene product is a component of virus particles.
J. Gen. Virol.
75:2047-2052[Abstract/Free Full Text].
|
| 15.
|
Olmsted, J. B.
1986.
Analysis of cytoskeletal structures using blot-purified monospecific antibodies.
Methods Enzymol.
134:467-472[Medline].
|
| 16.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed., p. 18.74.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 17.
|
Schmitz, J. B.,
A. G. Albright,
P. R. Kinchington, and F. J. Jenkins.
1995.
The UL37 protein of herpes simplex virus type 1 is associated with the tegument of purified virions.
Virology
206:1055-1065[Medline].
|
| 18.
|
Shelton, L.,
A. G. Albright,
W. T. Ruyechan, and F. J. Jenkins.
1994.
Retention of the herpes simplex virus type 1 (HSV-1) UL37 protein on single-stranded DNA columns requires the HSV-1 ICP8 protein.
J. Virol.
68:521-525[Abstract/Free Full Text].
|
| 19.
|
Shelton, L.,
M. N. Pensiero, and F. J. Jenkins.
1990.
Identification and characterization of the herpes simplex virus type 1 protein encoded by the UL37 open reading frame.
J. Virol.
64:6101-6109[Abstract/Free Full Text].
|
| 20.
|
Smith, D. B., and K. S. Johnson.
1988.
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione-S-transferase.
Gene
67:31-40[Medline].
|
| 21.
|
Somogyi, P., and H. Takagi.
1982.
A note on the use of picric acid-paraformaldehyde-glutaraldehyde fixative for correlated light and electron microscopic immunocytochemistry.
Neuroscience
7:1779-1783[Medline].
|
| 22.
|
Straus, S. E.,
H. S. Aulakh,
W. T. Ruychan,
J. Hay,
T. A. Casey,
G. F. Vande Woude,
J. Owens, and H. A. Smith.
1981.
Structure of varicella virus DNA.
J. Virol.
40:516-525[Abstract/Free Full Text].
|
| 23.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from acrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 24.
|
Vafai, A.,
Z. Wroblewska,
M. Wellish,
M. Green, and D. H. Gilden.
1984.
Analysis of three late varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3.
J. Virol.
52:953-959[Abstract/Free Full Text].
|
J Virol, August 1998, p. 6832-6837, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ou, Y., Davis, K. A., Traina-Dorge, V., Gray, W. L.
(2007). Simian Varicella Virus Expresses a Latency-Associated Transcript That Is Antisense to Open Reading Frame 61 (ICP0) mRNA in Neural Ganglia of Latently Infected Monkeys. J. Virol.
81: 8149-8156
[Abstract]
[Full Text]
-
Hambleton, S., Gershon, A. A.
(2005). Preventing Varicella-Zoster Disease. Clin. Microbiol. Rev.
18: 70-80
[Abstract]
[Full Text]
-
Xia, D., Srinivas, S., Sato, H., Pesnicak, L., Straus, S. E., Cohen, J. I.
(2002). Varicella-Zoster Virus Open Reading Frame 21, Which Is Expressed during Latency, Is Essential for Virus Replication but Dispensable for Establishment of Latency. J. Virol.
77: 1211-1218
[Abstract]
[Full Text]
-
Cohrs, R. J., Wischer, J., Essman, C., Gilden, D. H.
(2002). Characterization of Varicella-Zoster Virus Gene 21 and 29 Proteins in Infected Cells. J. Virol.
76: 7228-7238
[Abstract]
[Full Text]
-
Hanson, L. K., Slater, J. S., Karabekian, Z., Ciocco-Schmitt, G., Campbell, A. E.
(2001). Products of US22 Genes M140 and M141 Confer Efficient Replication of Murine Cytomegalovirus in Macrophages and Spleen. J. Virol.
75: 6292-6302
[Abstract]
[Full Text]